[Treatment of anemia in chronically dialyzed patients].
Moynot
A
A
AURA, Centre Henri Kuntizger, Commission de dialyse de la Société de néphrologie, Paris.
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000747:Anemia, Hypochromic / Q000209:etiology / Q000628:therapy; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001803:Blood Transfusion; D002318:Cardiovascular Diseases / Q000150:complications / Q000628:therapy; D003131:Combined Modality Therapy; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007501:Iron / Q000627:therapeutic use; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D009748:Nutrition Disorders / Q000150:complications; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
D000959:Antihypertensive Agents; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron
Traitement de l'anémie des dialysés chroniques.